STUDIES ON ENVIRONMENTAL TOXICANTS AND THE IMMUNE SYSTEM
NIH GUIDE, Volume 23, Number 11, March 18, 1994
PA NUMBER: PA-94-049
P.T. 34
Keywords:
Immune System
Environmental Effects
National Institute of Environmental Health Sciences
National Institute of Allergy and Infectious Diseases
PURPOSE
The National Institute of Environmental Health Sciences (NIEHS) and
the National Institute of Allergy and Infectious Diseases (NIAID)
announce their interest in receiving individual research grant
applications for support of studies on the interactions between
environmental substances and their effects on immune function, which
last appeared in the NIH Guide, Vol. 20, No. 23, June 14, 1991, Page
5. The objective is to promote research at the molecular and
cellular level to better understand mechanisms of
environmentally-induced aberrations within the immune system in order
to gain insight into approaches to mitigate the effects of such
agents. These agents are substances that may be present in the
natural environment or have been added by human activities and are
known to or are suspected of inducing illnesses that affect or
involve the immune systems.
The NIAID is the principal agency that supports fundamental research
concerned with the structure and function of the immune system in
health and disease. The acquisition of new and deeper knowledge
about the immune system is requisite to the development of improved
procedures for prevention, diagnosis and treatment of immunological
diseases and of diseases having a major immunological component. The
interest of the NIAID in environmental toxicology is predicated on
the strong likelihood that the analysis of interactions between
noxious substances in the environment and the immune system can
provide insight, from a largely-ignored perspective, on some of the
typical functions of the immune system, the adaptability and
plasticity of the immune system, and the susceptibility of the immune
system to abnormalities induced by chemical and physical insult.
The NIEHS is the principal Federal funding agency for support of
basic research on environmental factors that contribute to human
health problems and disease. Major emphasis by NIEHS is placed upon
research examining those physical and chemical substances resulting
from industrial progress. However, there also are many natural
environmental substances which have been found to have deleterious
effects on human health and are within the purview of the NIEHS
mission. Many of these substances cause human health problems by
disrupting normal immune function which can lead to a disease state.
HEALTHY PEOPLE 2000
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas. This PA,
Studies on Environmental Toxicants and the Immune System, is related
to the priority area of environmental health. Potential applicants
may obtain a copy of "Healthy People 2000" (Full Report: Stock No.
017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington DC 20402-9325 (telephone 202-783-3238).
ELIGIBILITY REQUIREMENTS
Applications may be submitted by domestic and foreign for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of state or local
governments, and eligible agencies in the Federal government.
Foreign institutions are not eligible for First Independent Research
Support and Transition (FIRST) (R29) awards. Applications from
minority individuals and women are encouraged.
MECHANISM OF SUPPORT
This PA will use the National Institutes of Health (NIH) individual
research grant (R01) and FIRST (R29) award. Responsibility for
planning, direction, and execution of the proposed project will be
solely that of the applicant.
RESEARCH OBJECTIVES
The effects of environmental toxicants may be divided into three
broad categories: suppression/inhibition of immunological competence;
initiation or triggering of autoimmunity; and stimulation of
allergic/hypersensitivity reactions. Although the NIEHS and NIAID
have overlapping interests with respect to each of these categories
of effect, it is reasonable to state that the interests of NIEHS
center on the effects of chemical/physical agents that suppress or
reduce the capacity of the immune system. The interests of NIAID are
more focussed on the actions of chemical/physical agents that
precipitate or lead to autoimmune and allergic disorders. NIEHS's
interests are to identify and characterize the mechanisms of action
of substances that affect the immune system and to determine the
magnitude and consequences of exposure to such substances. NIAID is
concerned with understanding the immuno-physiological processes that
are affected by environmental agents and elucidating the pathogenesis
of the disorders that they cause. Both Institutes are interested in
approaches that may mitigate the noxious effects of environmental
agents and in the development of improved animal and in vitro models
for studying the effects of noxious substances.
Research Goals and Scope
These applications should emphasize mechanisms rather than mere
descriptions of processes. They should utilize state-of-the-art
immunology, biochemistry, and molecular biology in such
investigations.
The following are examples of projects/topics that would be of
interest but are not meant to present the full range of
possibilities:
o Determine the mechanisms by which toxicants affect individual
components of the immune system; e.g., on cellular components such as
antigen-processing cells (APC), B- lymphocytes and T-lymphocytes.
o Identification of the actual immunogenic components (fragments,
molecular conjugates, etc.) and epitopes of toxicants that trigger
allergic/hypersensitive responses or autoimmunity, and detailed
analyses of their processing by APC and presentation to T- and
B-cells.
o Development of in vitro systems for systematic quantitative
analyses and mechanisms of action of toxicants on individual cellular
components of the immune system: APC, B-cells and T-cells.
o Comprehensive studies on toxicant-induced allergic/hypersensitive
responses designed to reveal the roles of components such as T-cells,
APC, IgE-producing B- cells, IgE molecules, leukocytes and mediator
substances in the development and manifestation of those responses.
o Development of approaches to prevent or reduce the undesirable
effects of toxicants on the immune system; e.g., appropriate
pre-immunization ("vaccination") against toxicants or preparation of
monoclonal antibodies capable of nullifying the effects of toxicants.
o Evaluation of the effects of "natural" levels of toxins on the
immune system.
o Studies on the genetics of susceptibility and resistance to the
effects of toxic substances.
o Studies on the genetic control of susceptibility and resistance to
those effects of toxicants that lead to autoimmune or allergic
disorders.
o Studies on the pharmacologic control of susceptibility of the
immune system to toxic substances.
o Studies on dual effects of toxic agents such as simultaneous
inactivation of certain components of the immune system and
activation of other components.
o Studies on toxicant-triggered expression of stress proteins (e.g.,
heat-shock proteins) and special receptors such as those for aromatic
hydrocarbons controlled by the "Ah" genetic locus and found in
leukocytes; and the roles of such protein in the effects of toxicants
on immune functions.
o Studies on aberrations in the elaboration and functions of
cytokines and cytokine receptors induced by toxicants.
o Synergistic actions of physical/chemical agents either with each
other (e.g., a chemical and UV-B or two chemicals) or with other
agents such as viruses or oncogenes.
STUDY POPULATIONS
INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN
SUBJECTS
It is the policy of the NIH that women and members of minority groups
and their subpopulations must be included in all NIH supported
biomedical and behavioral research projects involving human subjects,
unless a clear and compelling rationale and justification is provided
that inclusion is inappropriate with respect to the health of the
subjects or the purpose of the research. This new policy results
from the NIH Revitalization Act of 1993 (Section 492B of Public Law
103-43) and supersedes and strengthens the previous policies
(Concerning the Inclusion of Women in Study Populations, and
Concerning the Inclusion of Minorities in Study Populations), which
have been in effect since 1990. The new policy contains some
provisions that are substantially different from the 1990 policies.
All investigators proposing research involving human subjects should
read the "NIH Guidelines For Inclusion of Women and Minorities as
Subjects in Clinical Research," which have been published in the
Federal Register of March 9, 1994 (FR 59 11146-11151) and reprinted
in the NIH Guide for Grants and Contracts, Volume 23, Number 11,
March 18, 1994.
Investigators also may obtain copies of the policy from the program
staff listed under INQUIRIES. Program staff may also provide
additional relevant information concerning the policy.
(NOTE: When the proposed study or studies in the RFA or PA involves
a gender specific study or a single or limited number of minority
population groups, this should also be stated to inform potential
applicants and reviewers.)
Animal Welfare Considerations
Investigators are encouraged to consider alternative methods and
approaches in their research applications that do not require the use
of whole animals, use alternative species such as nonmammals or
invertebrates, reduce the number of animals required, and incorporate
refinements to procedures that will result in the elimination or
further minimization of pain and distress to animals.
APPLICATION PROCEDURES
Applications are to be submitted on form PHS 398 (rev. 9/91), which
is available in the office of sponsored research at most academic and
research institutions and from the Office of Grants Information,
Division of Research Grants, National Institutes of Health, Westwood
Building, Room 449, Bethesda, MD 20892, telephone 301/710-0267. To
identify the application as a response to this program announcement,
check "YES" in Item 2a on the face page of the application and enter
the program announcement title number. Applications will be accepted
in accordance with the usual receipt dates for new research grant
applications; i.e., February 1, June 1, and October 1. The earliest
possible award dates will be approximately nine months after the
respective receipt dates. Applications received too late for one
cycle of review will be held until the next receipt date.
Applications for the FIRST Award (R29) must include at least three
sealed letters of reference attached to the face page of the original
application. FIRST Award (R29) applications submitted without the
required number of reference letters will be considered incomplete
and will be returned without review. Applications will be received
by the NIH Division of Research Grants (DRG) and referred to an
appropriate study section for scientific and technical merit review.
Institute assignment decisions will be governed by normal
programmatic considerations as specified in the NIH Referral
Guidelines.
The original and five copies of the application must be sent to:
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**
REVIEW CONSIDERATIONS
The review criteria customarily employed by the NIH for regular
research grant applications will prevail. Following the initial
scientific review, the applications will be evaluated by the
appropriate National Advisory Council.
AWARD CRITERIA
Applications will compete for available funds with all other approved
applications assigned to that ICD. The following will be considered
making funding decisions:
o Quality of the proposed project as determined by peer review.
o Availability of funds
o Program balance among research areas of he announcement
INQUIRIES
Written and telephone inquiries are encouraged. The opportunity to
clarify any issues or questions from potential applicants is welcome.
Direct inquiries regarding programmatic issues to:
Dr. Eugene M. Zimmerman
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Solar Building, Room 4A24
Bethesda, MD 20892
Telephone: (301) 496-8973
FAX: (301) 402-2571
Dr. Jerry A. Robinson
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-7724
FAX: (919) 541-2843
To better ensure appropriate Program and Institute assignment,
applicants may submit a letter of intent and/or a copy of the
application face page to the Program Administrator, NIAID or NIEHS.
Direct inquiries regarding fiscal matters to:
David L. Mineo
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233
Research Triangle Park, NC 27709
Telephone: (919) 541-1373
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic
Assistance Numbers 93.112, Characterization of Environmental Health
Hazards; 93.113, Biological Response to Environmental Health Hazards;
and 93.855, Allergy, Immunology and Transplantation Research. Awards
are made under the authority of Section 487, Public Health Service
Act as amended (42 USC 288) and administered under PHS grants
policies and Title 42 of the Code of Federal Regulations, Part 66.
This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency
review.
.
Return to NIH Guide Main Index
|
Office of Extramural Research (OER) |
|
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
|
Department of Health and Human Services (HHS) |
|
||||